In December 2025, Eli Lilly reported that retatrutide — their investigational triple-agonist peptide — produced an average weight loss of 71.2 pounds in its first successful Phase 3 trial, with meaningful relief from osteoarthritis pain as a secondary outcome. That’s roughly double what first-generation GLP-1 agonists like semaglutide produce in comparable timelines, and it has reshaped the entire weight-loss and metabolic research landscape heading into 2026.
For laboratory researchers, retatrutide — also cataloged under the research designation GLP-3R or Reta GLP-3R — has become one of the most requested investigational peptides of the year. Availability is limited, sourcing standards vary wildly across suppliers, and the regulatory picture is shifting month-to-month. This guide walks through what the peer-reviewed literature actually shows, how retatrutide differs mechanistically from GLP-1 and dual-agonist peptides, and what researchers should understand before ordering Reta GLP-3R for laboratory investigation.
A note before we start: Retatrutide is an investigational drug. It is not FDA-approved for any human or veterinary use. Research-grade Reta GLP-3R is sold strictly for in-vitro laboratory investigation and is not intended for human or animal administration. Nothing in this article constitutes medical advice.
Free Tool
Peptide Reconstitution Calculator
Convert vial strength, water volume, and desired dose into precise syringe units. Works for BPC-157, TB-500, GHK-Cu, and all research peptides.
Try the Calculator →What is retatrutide?
Retatrutide is a synthetic 39-amino-acid peptide developed by Eli Lilly. Structurally, it is a chemically modified analog of GIP (glucose-dependent insulinotropic polypeptide), engineered to bind three distinct incretin-system receptors at once:
- GLP-1 receptor (the same target as semaglutide, liraglutide, tirzepatide)
- GIP receptor (the second target hit by tirzepatide)
- Glucagon receptor (the new third target that makes retatrutide distinct)
That third target is why you will see retatrutide referred to in research literature as a triple-agonist or triple-receptor agonist, and why vendor catalogs have adopted the designation “GLP-3R” — it is not a reference to a receptor called GLP-3, but to the fact that retatrutide is the third generation of GLP-class agonists, adding glucagon receptor activity on top of the GLP-1/GIP activity that tirzepatide introduced.
The glucagon component is mechanistically important. Glucagon receptor activation increases energy expenditure and lipolysis, which appears to be responsible for the outsized weight loss observed in clinical trials compared to GLP-1-only agonists. It is also why retatrutide has generated interest in osteoarthritis and hepatic steatosis indications beyond simple weight management.
What the Phase 3 data actually shows
Lilly’s December 2025 Phase 3 readout was the clinical inflection point. Participants receiving the 12 mg weekly dose achieved an average weight loss of approximately 36.6 lbs, equivalent to 16.8% of baseline body weight over the trial period. Participants on higher doses in the long-duration arm reached average weight loss of 71.2 lbs.
Secondary endpoints were also striking. Trial participants with baseline osteoarthritis reported statistically significant reductions in pain scores, which Lilly is now investigating in a dedicated Phase 3 osteoarthritis trial. Additional Phase 3 programs are underway for type 2 diabetes, chronic low back pain, moderate-to-severe obstructive sleep apnea, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease (MASLD).
Seven additional Phase 3 trials evaluating once-weekly retatrutide in obesity and type 2 diabetes are expected to complete in 2026.
Retatrutide vs. GLP-1 vs. tirzepatide: what the research literature shows
The cleanest way to understand retatrutide’s place in the incretin-agonist landscape is to compare it against the two established classes:
| Peptide class | Primary receptors | Representative molecule | Approximate average weight loss at peak trial dose |
|---|---|---|---|
| GLP-1 agonist | GLP-1R | Semaglutide | ~15% of baseline body weight |
| GLP-1/GIP dual agonist | GLP-1R + GIP-R | Tirzepatide | ~20-22% of baseline body weight |
| GLP-1/GIP/Glucagon triple agonist | GLP-1R + GIP-R + Glucagon-R | Retatrutide | Up to ~24% in published Phase 2, higher in long-duration Phase 3 |
Published meta-analyses (see the 2025 systematic review in PMC12026077) confirm that the glucagon receptor component is what differentiates retatrutide’s efficacy from tirzepatide. The same literature notes that triple-agonism also introduces a wider adverse-event profile, primarily in the gastrointestinal and hepatic systems, which is an important consideration for any mechanistic or toxicology research program.
Why “Reta GLP-3R” is the research designation
Retatrutide is not yet FDA-approved and is not legally available for public use or compounding. Any product marketed to consumers as “retatrutide” outside of a clinical trial is unauthorized and unsafe.
For laboratory research, however, synthetic retatrutide is produced by a small number of peptide manufacturers for in-vitro investigation. Because of trademark and regulatory sensitivity around the name “retatrutide,” many research suppliers use the research designation GLP-3R as a catalog name. Umbrella Labs formally announced this designation in February 2026, and it has since been adopted broadly across the research peptide industry.
When researchers see “Reta GLP-3R” on a vendor catalog, it refers to synthetic retatrutide sold for laboratory research use only. Labeling standards, purity specs, and quality control still vary significantly between suppliers.
What to look for when sourcing Reta GLP-3R for research
The research peptide space experienced significant supply disruption in the first quarter of 2026. Peptide Sciences — the largest research peptide vendor in the United States by volume — posted a shutdown notice in March 2026 and exited the market, concentrating research demand on a smaller set of remaining suppliers. At the same time, HHS reclassified BPC-157 from FDA Category 2 back to Category 1 in February 2026, which adjacent-demand-shifted attention back onto compounding-eligible peptides and away from investigational ones like retatrutide.
For researchers evaluating Reta GLP-3R sourcing in 2026, the benchmarks are:
1. ≥99% HPLC-verified purity, with the chromatogram available on request or published publicly per batch. 2. Mass spectrometry identity confirmation — a molecular weight match is the baseline evidence that what is in the vial is actually retatrutide, not a homolog or truncated fragment. 3. Independent third-party Certificate of Analysis (COA) — preferably from an accredited analytical lab, not from the manufacturer’s in-house QC. 4. USP <85> endotoxin and USP <71> sterility testing for any peptide that may be used in cell-culture or animal-model work. 5. Clear research-use-only labeling and sourcing documentation that does not market to human or veterinary end-use.
Any supplier that does not meet these baselines should be avoided. At Prax Peptides, every Reta GLP-3R lot is tested by HPLC and LC-MS, and the COA is available for each batch.
Prax Reta GLP-3R product lineup
For researchers investigating retatrutide in laboratory models, Prax offers three strength variants to match study design requirements:
- Reta GLP-3R 5mg — for low-dose receptor-binding studies or pilot titration work
- Reta GLP-3R 10mg — the standard strength for most in-vitro and cell-culture applications
- Reta GLP-3R 20mg — for extended-timeline studies or laboratories running parallel dose arms
All three variants are synthesized to ≥99% HPLC-verified purity and ship with batch-specific analytical documentation.
Frequently asked questions
Is retatrutide the same as “GLP-3R”? Yes. “GLP-3R” is the research-catalog designation for retatrutide adopted by many research peptide suppliers in 2026. The molecule is identical; the name reflects its status as the third generation of GLP-class agonists.
Is retatrutide FDA-approved? No. As of April 2026, retatrutide is in Phase 3 clinical trials across multiple indications. It is not legally available for human or veterinary use outside of enrollment in an active clinical trial.
How is retatrutide different from tirzepatide (Mounjaro/Zepbound)? Tirzepatide is a dual agonist targeting GLP-1 and GIP receptors. Retatrutide adds a third target — the glucagon receptor — which appears responsible for the increased weight-loss effect in trial data.
Can I legally purchase retatrutide? Research-grade Reta GLP-3R is sold strictly for in-vitro laboratory research and is not for human or veterinary administration. Any product marketed directly to consumers for personal use is illegal and unsafe.
What storage conditions does Reta GLP-3R require? Lyophilized Reta GLP-3R is stable at refrigerated temperatures for extended periods. Once reconstituted, it should be stored at 2-8°C and used within the timeframe specified on the Certificate of Analysis.
How does retatrutide compare to BPC-157 or other research peptides? They target entirely different systems. Retatrutide acts on incretin and glucagon receptors for metabolic research; BPC-157 is a gastric-derived pentadecapeptide investigated primarily in tissue-repair and angiogenesis research. They are not substitutes for one another.
The bottom line
Retatrutide is the most significant new investigational peptide of 2026. The Phase 3 weight-loss data is exceptional, the secondary-indication breadth is unusual for a single molecule, and the triple-agonist mechanism represents a genuine pharmacological advance over GLP-1 and dual-agonist predecessors. For laboratory researchers investigating incretin pharmacology, metabolic disease models, or comparative agonist studies, access to high-purity Reta GLP-3R has become a bottleneck — and quality of sourcing varies dramatically.
For researchers who want to go deeper, our GLP-1 peptides research article covers the foundational pharmacology of the incretin class, and our peptide calculator assists with reconstitution planning across all Prax research peptides.
All Prax Peptides products are intended for laboratory research use only. They are not drugs, supplements, or food products, and are not for human or veterinary consumption. Please review our full research-use terms before ordering.